Bunkerhill ECG-EF vs VX1+
AI Verdict
Choose Bunkerhill ECG-EF if…
Choose Bunkerhill ECG-EF if your primary goal is to rapidly and non-invasively screen a broad patient population for early signs of reduced left ventricular ejection fraction, indicating potential heart failure risk. This tool is ideal for integrating into routine clinical workflows within general cardiology, emergency medicine, or internal medicine to proactively identify at-risk patients from standard ECGs.
View Bunkerhill ECG-EF →Choose VX1+ if…
Choose VX1+ if you are an electrophysiologist seeking real-time, AI-powered assistance during complex cardiac ablation procedures for atrial fibrillation or tachycardia. This software is specifically designed to enhance procedural efficacy by identifying abnormal electrograms on 3D maps, aiding in precise ablation targeting during interventional procedures.
View VX1+ →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Bunkerhill ECG-EF | VX1+ |
|---|---|---|
| Pricing | Contact sales for pricing details. | Unknown |
| Deployment | Cloud-native platform (Carebricks) that integrates with existing health system infrastructure like EHRs. | Software, compatible with most multipolar catheters and mapping technologies used in operating rooms or electrophysiology labs. |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Bunkerhill ECG-EFBunkerhill ECG-EF emphasizes seamless integration with EHRs and clinical archives, supporting automated clinical workflows for a broad range of medical specialties. Its software-only nature and use of routine ECG data suggest a low barrier to adoption and minimal disruption to existing processes for widespread screening. While VX1+ offers a simple user interface and compatibility within specialized EP labs, Tool A's broader accessibility and integration into general clinical workflows for early detection give it an edge in overall usability.
Clinical Value
VX1+Both tools are FDA-cleared and offer significant clinical value. However, VX1+ has demonstrated superior efficacy in improving treatment outcomes for persistent atrial fibrillation through the TAILORED-AF randomized controlled trial, showing 88% freedom from AF at 12 months with AI-guided ablation compared to 70% in the conventional group. This direct impact on the success rate of a complex therapeutic procedure, supported by a large-scale randomized trial, gives it a stronger claim in terms of demonstrated clinical impact compared to Bunkerhill ECG-EF's validated screening capabilities for heart failure risk.
Pricing & Value
TieNeither Bunkerhill ECG-EF nor VX1+ publicly discloses their pricing information; both require contacting the vendor for details. Without transparent pricing models, subscription structures, or publicly available cost-effectiveness analyses for either product, it is impossible to conduct a meaningful head-to-head comparison of their pricing and overall value.
Enterprise Readiness
Bunkerhill ECG-EFBunkerhill ECG-EF explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), and it integrates seamlessly with EHRs and clinical archives. Furthermore, it is part of the Carebricks platform, which is broadly deployed at major health systems like UTMB Health, Cleveland Clinic, and Mayo Clinic, enabling enterprise-scale AI workflows across various clinical and operational domains. VX1+'s compliance is only 'expected' in the provided data, and its integration is more specialized to EP systems, indicating a less comprehensive enterprise offering.
Innovation
VX1+While Bunkerhill ECG-EF's use of 'Generative AI' for early heart failure detection from routine ECGs is innovative in its scalability and accessibility, VX1+ stands out for its real-time AI assistance during live, complex cardiac ablation procedures. This application directly guides electrophysiologists in a high-stakes interventional setting, aiming to standardize and improve the efficacy of a challenging therapeutic intervention, which is a groundbreaking use of AI in interventional cardiology.
Support & Docs
VX1+Volta Medical's VX1+ explicitly provides a 'User Manual' and a 'Documentation' portal with a 'User guide' and 'Reference' on its website, along with contact information for support. In contrast, the provided information for Bunkerhill ECG-EF does not include any specific details regarding available support resources or documentation. Therefore, VX1+ demonstrates more transparent and accessible support and documentation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Bunkerhill ECG-EF | VX1+ |
|---|---|---|
| Name | Bunkerhill ECG-EF | VX1+ |
| Company | BunkerHill Health | Volta Medical |
| Description | FDA-cleared artificial intelligence algorithm that detects reduced left ventricular ejection fraction (LVEF u2264 40%) from routine 12-lead electrocardiograms (ECGs), aiding in the early identification of patients at risk for heart failure. | AI-powered software that assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for atrial fibrillation and atrial tachycardia. |
| Primary Function | Detects reduced Left Ventricular Ejection Fraction (LVEF u2264 40%) from routine 12-lead ECGs. | Assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures. |
| Specialties | Cardiology, Emergency Medicine, Internal Medicine | Cardiology |
Videos
Demos, reviews, and walkthroughs featuring Bunkerhill ECG-EF and VX1+.